Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 69

1.

APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy.

Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerrière A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D.

Nat Genet. 2006 Jan;38(1):24-6. Epub 2005 Dec 20.

PMID:
16369530
2.

Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice.

Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, Tan J.

J Neurosci. 2005 Sep 21;25(38):8807-14.

3.

Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy.

Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, Bacskai BJ, Hyman BT.

J Neurosci. 2005 Aug 3;25(31):7278-87.

4.

The synaptic Abeta hypothesis of Alzheimer disease.

Tanzi RE.

Nat Neurosci. 2005 Aug;8(8):977-9. No abstract available.

PMID:
16047022
5.

Abeta42 is essential for parenchymal and vascular amyloid deposition in mice.

McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C, Skipper L, Murphy MP, Beard J, Das P, Jansen K, DeLucia M, Lin WL, Dolios G, Wang R, Eckman CB, Dickson DW, Hutton M, Hardy J, Golde T.

Neuron. 2005 Jul 21;47(2):191-199. doi: 10.1016/j.neuron.2005.06.030.

6.

Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production.

Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE.

Nat Med. 2005 May;11(5):545-50. Epub 2005 Apr 17.

PMID:
15834426
7.

Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.

Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, Mehta PD, Buxbaum J, Haroutunian V, Nixon RA.

Neurobiol Aging. 2004 Nov-Dec;25(10):1263-72.

PMID:
15465622
8.

BACE1: the beta-secretase enzyme in Alzheimer's disease.

Vassar R.

J Mol Neurosci. 2004;23(1-2):105-14. Review.

PMID:
15126696
9.

Down syndrome and beta-amyloid deposition.

Head E, Lott IT.

Curr Opin Neurol. 2004 Apr;17(2):95-100. Review.

PMID:
15021233
10.

Risk factors for dementia in people with down syndrome: issues in assessment and diagnosis.

Bush A, Beail N.

Am J Ment Retard. 2004 Mar;109(2):83-97. Review.

PMID:
15000668
11.

Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients.

Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, Beach T, Sue L, Sabbagh M, Cai H, Wong P, Price D, Shen Y.

Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3632-7. Epub 2004 Feb 20.

12.

Beta-secretase activity increases with aging in human, monkey, and mouse brain.

Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC.

Am J Pathol. 2004 Feb;164(2):719-25.

13.

VEGF is necessary for exercise-induced adult hippocampal neurogenesis.

Fabel K, Fabel K, Tam B, Kaufer D, Baiker A, Simmons N, Kuo CJ, Palmer TD.

Eur J Neurosci. 2003 Nov;18(10):2803-12.

PMID:
14656329
14.
15.

Parallel compensatory and pathological events associated with tau pathology in middle aged individuals with Down syndrome.

Head E, Lott IT, Hof PR, Bouras C, Su JH, Kim R, Haier R, Cotman CW.

J Neuropathol Exp Neurol. 2003 Sep;62(9):917-26.

PMID:
14533781
16.

Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice.

Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE.

J Neurosci. 2003 Sep 17;23(24):8532-8.

17.

BACE-2 is overexpressed in Down's syndrome.

Barbiero L, Benussi L, Ghidoni R, Alberici A, Russo C, Schettini G, Pagano SF, Parati EA, Mazzoli F, Nicosia F, Signorini S, Feudatari E, Binetti G.

Exp Neurol. 2003 Aug;182(2):335-45.

PMID:
12895444
18.

App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome.

Cataldo AM, Petanceska S, Peterhoff CM, Terio NB, Epstein CJ, Villar A, Carlson EJ, Staufenbiel M, Nixon RA.

J Neurosci. 2003 Jul 30;23(17):6788-92.

19.

Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production.

Grbovic OM, Mathews PM, Jiang Y, Schmidt SD, Dinakar R, Summers-Terio NB, Ceresa BP, Nixon RA, Cataldo AM.

J Biol Chem. 2003 Aug 15;278(33):31261-8. Epub 2003 May 20.

20.

Characteristic developmental expression of amyloid beta40, 42 and 43 in patients with Down syndrome.

Hirayama A, Horikoshi Y, Maeda M, Ito M, Takashima S.

Brain Dev. 2003 Apr;25(3):180-5.

PMID:
12689696

Supplemental Content

Support Center